- Home
- RSF vs FBIO Comparison
RSF vs FBIO Comparison
Compare RSF & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSF
- FBIO
- Stock Information
- Founded
- RSF 2016
- FBIO 2006
- Country
- RSF United States
- FBIO United States
- Employees
- RSF N/A
- FBIO N/A
- Industry
- RSF Investment Managers
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- RSF Finance
- FBIO Health Care
- Exchange
- RSF Nasdaq
- FBIO Nasdaq
- Market Cap
- RSF 53.1M
- FBIO 49.1M
- IPO Year
- RSF N/A
- FBIO N/A
- Fundamental
- Price
- RSF $15.17
- FBIO $1.69
- Analyst Decision
- RSF
- FBIO Strong Buy
- Analyst Count
- RSF 0
- FBIO 3
- Target Price
- RSF N/A
- FBIO $21.00
- AVG Volume (30 Days)
- RSF 11.8K
- FBIO 145.3K
- Earning Date
- RSF 01-01-0001
- FBIO 05-19-2025
- Dividend Yield
- RSF 10.61%
- FBIO N/A
- EPS Growth
- RSF N/A
- FBIO N/A
- EPS
- RSF N/A
- FBIO N/A
- Revenue
- RSF N/A
- FBIO $57,675,000.00
- Revenue This Year
- RSF N/A
- FBIO $63.20
- Revenue Next Year
- RSF N/A
- FBIO $66.70
- P/E Ratio
- RSF N/A
- FBIO N/A
- Revenue Growth
- RSF N/A
- FBIO N/A
- 52 Week Low
- RSF $14.81
- FBIO $1.33
- 52 Week High
- RSF $16.23
- FBIO $2.89
- Technical
- Relative Strength Index (RSI)
- RSF 49.67
- FBIO 52.97
- Support Level
- RSF $15.10
- FBIO $1.67
- Resistance Level
- RSF $15.36
- FBIO $1.84
- Average True Range (ATR)
- RSF 0.11
- FBIO 0.09
- MACD
- RSF -0.00
- FBIO 0.01
- Stochastic Oscillator
- RSF 34.93
- FBIO 58.54
About RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.